Last reviewed · How we verify
NCT04936607: NEPTUNE
ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions
NA trial testing Personalized hydration strategy in Contrast-Induced Acute Kidney Injury in 1,158 participants. Currently enrolling.
30 January 2027
Quick facts
| Lead sponsor | Montreal Heart Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 1,158 |
| Start date | 28 June 2021 |
| Primary completion | 30 January 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Personalized hydration strategy
- Standard of care
Conditions studied
- Contrast-Induced Acute Kidney Injury — all drugs for Contrast-Induced Acute Kidney Injury →
Sponsor
Montreal Heart Institute
Who can join
18 and older, any sex, with Contrast-Induced Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04936607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Contrast-Induced Acute Kidney Injury
Currently open trials in the same condition.
- NCT07231939 — Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI · recruiting
Other Montreal Heart Institute trials
Trials by the same sponsor.
- NCT07524335 — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial · Phase 3 · not yet recruiting
- NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
- NCT07391358 — DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid · NA · not yet recruiting
- NCT05450328 — Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation · Phase 2 · not yet recruiting
- NCT07144722 — Prehabilitation Program for Patients Awaiting Elective Heart Surgery at Increased Risk of Postoperative Complications: F · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04936607 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Montreal Heart Institute
- Last refreshed: 8 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04936607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing